# Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

> **NCT01410227** · PHASE3 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 49 (actual)

## Conditions studied

- Von Willebrand Disease

## Interventions

- **BIOLOGICAL:** Recombinant von Willebrand factor (rVWF)
- **DRUG:** Placebo
- **BIOLOGICAL:** Recombinant factor VIIII (rFVIII)

## Key facts

- **NCT ID:** NCT01410227
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-01
- **Primary completion:** 2014-02-01
- **Final completion:** 2014-02-01
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2021-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01410227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01410227, "Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01410227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*